1984
由安吉-瑞迪博士创立- 公司的第一种分子是甲基多巴，这是一种高血压药物，1984年之前在印度是没有的。 该API已被供应给全球领先的制药公司。
1991
从API到制剂 - 推出Omez（奥美拉唑）。 瑞迪博士增加制剂能力
1995
扩展到美国、欧洲、俄罗斯和欧洲市场
2001
第一个日本以外在纽约证券交易所上市的亚太制药公司
2010
瑞迪博士宣布在美国市场推出氨氯地平贝那普利。
瑞迪博士推出世界上第一款生物仿制药阿法达贝泊，为数百万贫血患者带来了福音，并在印度以“Cresp®”的品牌名称推出了印度唯一一家。
在活性成分业务方面，该公司在2009-10年度提交了36份药物主文件（DMF）。 截至2010年3月31日，瑞迪博士累计提交了378份DMF，其中156份在美国提交。
2011
瑞迪博士宣布推出泮托拉唑钠缓释片。
瑞迪博士在美国市场推出左西替利嗪片，这是Xyzal®的生物等效仿制版本。
10月23日，瑞迪博士收到了美国FDA对奥氮平20毫克片剂的批准，并获得了180天的市场专卖权。
2012
瑞迪博士宣布在美国市场推出阿托伐他汀钙片，这是一种LIPITOR®的生物等效仿制版本。
瑞迪博士宣布在美国市场推出琥珀酸美托洛尔ER（缓释）片，这是TopropXL®片的生物等效仿制版本。
2013
瑞迪博士宣布在美国市场推出Zenatane™（异维A酸胶丸USP），这是Accutane®的治疗等效仿制版本。
瑞迪博士宣布在美国市场推出双丙戊酸钠缓释片USP，这是Depakote® ER片的治疗等效仿制版本。
推出了104种新的仿制药产品。
2012-13财年提交了577份DMF。
2018
瑞迪博士实验室宣布在印度推出Hervycta®（曲妥珠单抗生物仿制药）。
瑞迪博士实验室获得批准，在美国市场推出阿司匹林和缓释双嘧达莫胶囊。
2019
瑞迪博士实验室宣布卡前列腺素氨丁三醇注射液USP，250微克/毫升（1毫升）单剂瓶在美国市场率先推出。
我们是第一家在中国赢得其中一种仿制药（奥氮平）供应国家招标的印度制药公司。
2020
瑞迪博士实验室宣布在美国市场率先推出盐酸纳洛酮注射液USP，2毫克/2毫升（1毫克/毫升）单剂量载药注射。
瑞迪博士实验室宣布在印度推出FXR™ (奥贝胆酸)。
瑞迪博士实验室宣布在印度推出AVIGAN® (法匹拉韦)。
瑞迪博士实验室宣布在印度推出Redyx。
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate, and severe COVID-19.
Our focus on agility, access, and affordability helped us reach over 5 million patients during the pandemic, especially in low- and middle-income countries.
Our biggest manufacturing facility in Hyderabad was recognized by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
We refreshed our ESG goals to make them bold, measurable, accountable, and central to business strategy.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech.
We launched Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-file, 180-day exclusivity.
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
We diversified our offerings to patients – women’s healthcare in the U.S., consumer healthcare and our first-ever biosimilar in the UK, and vaccines in India.
We agreed with Nestlé India to form a joint venture to introduce health science nutraceutical products to consumers across India and other agreed territories.
We signed a definitive agreement with Haleon plc to acquire Nicotinell and its related portfolio in Nicotine Replacement Therapy, in a significant step towards building a global consumer healthcare business, outside of the US. This is our biggest acquisition yet.
